Details for Patent: 10,265,293
✉ Email this page to a colleague
Which drugs does patent 10,265,293 protect, and when does it expire?
Patent 10,265,293 protects SYNDROS and is included in one NDA.
Summary for Patent: 10,265,293
Title: | Oral cannabinoid formulations |
Abstract: | Oral cannabinoid formulations, including an aqueous-based oral dronabinol solution, that are stable at room or refrigerated temperatures and may possess improved in vivo absorption profiles with faster onset and lower inter-subject variability. |
Inventor(s): | Goskonda; Venkat R. (Phoenix, AZ), Chavan; Ashok (Chandler, AZ), Kokate; Amit (Englewood, NJ), Gill; Howard (Scottsdale, AZ) |
Assignee: | INSYS DEVELOPMENT COMPANY, INC. (Chandler, AZ) |
Application Number: | 15/132,896 |
Patent Claim Types: see list of patent claims | Formulation; Delivery; |
Drugs Protected by US Patent 10,265,293
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Benuvia Operations | SYNDROS | dronabinol | SOLUTION;ORAL | 205525-001 | Mar 23, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |